This trial will determine if a single intramuscular (IM) administration of Engensis is safe and effective over the long term.
1 Primary · 3 Secondary · Reporting Duration: From the 7 days prior to the Day 0 Visit (Study VMDN-003-2) to the 7 days prior to the Day 270 Visit and the 7 days prior to the Day 365 Visit
Experimental Treatment
Non-Treatment Group
250 Total Participants · 2 Treatment Groups
Primary Treatment: Engensis · Has Placebo Group · Phase 3
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Virginia | 33.3% |
Pennsylvania | 22.2% |
California | 11.1% |
Other | 33.3% |
18 - 65 | 100.0% |
Innovative Research of West Florida, Inc. | 16.7% |
Clinical Trials - Little Rock | 16.7% |
Manassas Clinical Research Center | 33.3% |
Other | 33.3% |
Did not meet criteria | 42.9% |
Met criteria | 57.1% |
0 | 100.0% |
100.0% | |